Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.
The ongoing debate about the FDA approval of BiDil in 2005 demonstrates how the first racially/ethnically licensed drug is entangled in both Utopian and dystopian future visions about the continued saliency of race/ethnicity in science and medicine. Drawing on the sociology of expectations, this paper analyzes how scientists in the field of pharmacogenetics are constructing certain visions of the future with respect to the use of social categories of race/ethnicity and the impact of high-throughput genotyping technologies that promise to transform scientific practices.
Tutton
Richard
R
ESRC Centre for Economic and Social Aspects of Genomics (CESA-Gen), Institute for Advanced Studies, Lancaster University, Lancaster, UK.
Smart
Andrew
A
Martin
Paul A
PA
Ashcroft
Richard
R
Ellison
George T H
GT
D004338:Drug Combinations; D005828:Genetics, Population; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D010597:Pharmacogenetics; D044469:Racial Groups / Q000235:genetics*; D012723:Sex; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004338:Drug Combinations; D014665:Vasodilator Agents; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate